Flanostu personal page - To The Moon

Flanostu

No personal profile

16Follow

9Followers

0Topic

0Badge

12-04

Looking good

12-04

Major regulatory validation; merger and acquisitions appeal; supports global regulatory strategy; top tier milestone 💪

FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea

11-04

$GRAB 20251121 7.0 CALL$

11-01

Bullish on earnings. 21 Nov $7 call options 🤔

Sorry, the original content has been removed

07-30

Excuse the language. But faaark that's fantastic 👏

Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X

07-21

$CHWY 20250815 40.0 CALL$ will try & play this call again 😉

07-07

$INCANNEX HEALTHCARE LTD(IXHL)$ topped up with a small parcel on the pre market pullback 🫣

03-07

They need to make options tradable outside the standard hours as well

Sorry, the original content has been removed

02-13

$LCID 20250221 3.0 CALL$ taking small profits

02-12

$NVDA 20250221 130.0 CALL$ might do another quick flip today, maybe 🤔

01-28

$U 20250221 22.0 CALL$ sold too early again, but other options plays are looking better setup. Maybe 🤦‍♂️🤔

01-18

$DXB USA & China licensing deals still to come

$DXB share price continues to hold up well since the Japan licensing deal annoucement. Company continues to lock in multi-country licensing deals prior to final Phase readout [财迷]

$DXB USA & China licensing deals still to come

01-18

$NVDA 20250117 137.0 CALL$ Should've been over 100% profit but stuffed up my trade. Need to be more disciplined

01-08

$HAL 20250117 27.0 CALL$ profit should've been a lot higher but I got too greedy 😞

01-07

$XTI Aerospace, Inc.(XTIA)$ Sold too early but a small win to kick off 2025 🤔

01-02

USD 5 stock voucher. Good start to the year 💪

2024-11-21

$Occidental(OXY)$ Warren Buffet bought shares in the $60s, yet I'm waiting for it to break above $52 & stay there 🥴 Also, better-than-expected third-quarter earnings 🤷‍♂️

2024-11-20

$Tonix Pharmaceuticals(TNXP)$ Breaks 15c & it'll be on 😉

2024-10-29

$Cemtrex(CETX)$ Someone wants in 🤑

2024-10-24

$Cemtrex(CETX)$ Support 30c range, RSI oversold. Looking for a pop as it wants to move 💪 Gap $3.49-$5.23 🤤🤔

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4090118087808150","uuid":"4090118087808150","gmtCreate":1627015027286,"gmtModify":1680488148883,"name":"Flanostu","pinyin":"flanostu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":16,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.06","exceedPercentage":"60.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.06","exceedPercentage":"60.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":4,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":507169696534648,"gmtCreate":1764842415202,"gmtModify":1764842418993,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"Looking good&nbsp;","listText":"Looking good&nbsp;","text":"Looking good","images":[{"img":"https://community-static.tradeup.com/news/1001e39388f21422f90a3d23b2496753","width":"1242","height":"1879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/507169696534648","isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":507169331593976,"gmtCreate":1764842348449,"gmtModify":1764842352467,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"Major regulatory validation; merger and acquisitions appeal; supports global regulatory strategy; top tier milestone 💪","listText":"Major regulatory validation; merger and acquisitions appeal; supports global regulatory strategy; top tier milestone 💪","text":"Major regulatory validation; merger and acquisitions appeal; supports global regulatory strategy; top tier milestone 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/507169331593976","repostId":"2588049886","repostType":2,"repost":{"id":"2588049886","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1764766906,"share":"https://ttm.financial/m/news/2588049886?lang=&edition=fundamental","pubTime":"2025-12-03 21:01","market":"us","language":"en","title":"FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049886","media":"Reuters","summary":"Incannex Healthcare Inc. announced that the U.S. Food and Drug Administration  has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea . The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Grants <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation to <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> for IHL-42X in Obstructive Sleep Apnea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea (OSA). The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-117571), on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Grants <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation to <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> for IHL-42X in Obstructive Sleep Apnea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea (OSA). The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-117571), on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2JMx64:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2588049886","content_text":"FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea\n    \n\nIncannex Healthcare Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea (OSA). The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-117571), on December 03, 2025, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"IXHL":0.9}},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":496375082554232,"gmtCreate":1762207751356,"gmtModify":1762219474894,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/OPT/GRAB 20251121 7.0 CALL\">$GRAB 20251121 7.0 CALL$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/GRAB 20251121 7.0 CALL\">$GRAB 20251121 7.0 CALL$</a>&nbsp;","text":"$GRAB 20251121 7.0 CALL$","images":[{"img":"https://community-static.tradeup.com/news/297d25fb60c788743a79c8c59aafc8f1","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/496375082554232","isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":495445381021760,"gmtCreate":1761988929153,"gmtModify":1761988932855,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"Bullish on earnings. 21 Nov $7 call options 🤔","listText":"Bullish on earnings. 21 Nov $7 call options 🤔","text":"Bullish on earnings. 21 Nov $7 call options 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/495445381021760","repostId":"1160098839","repostType":2,"isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":462272078565528,"gmtCreate":1753877678434,"gmtModify":1753877682283,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"Excuse the language. But faaark that's fantastic 👏","listText":"Excuse the language. But faaark that's fantastic 👏","text":"Excuse the language. But faaark that's fantastic 👏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/462272078565528","repostId":"2555049322","repostType":2,"repost":{"id":"2555049322","kind":"live","pubTimestamp":1753876802,"share":"https://ttm.financial/m/news/2555049322?lang=&edition=fundamental","pubTime":"2025-07-30 20:00","market":"nz","language":"en","title":"Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X","url":"https://stock-news.laohu8.com/highlight/detail?id=2555049322","media":"THOMSON REUTERS","summary":"Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X","content":"<html><body><p>Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-30 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUA1YQT1J:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUA1YQT1J:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUA1YQT1J:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2555049322","content_text":"Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X","news_type":1,"symbols_score_info":{"IXHL":0.9}},"isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":459034328183416,"gmtCreate":1753105721800,"gmtModify":1753105725370,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/CHWY 20250815 40.0 CALL\">$CHWY 20250815 40.0 CALL$</a> will try &amp; play this call again 😉","listText":"<a href=\"https://ttm.financial/OPT/CHWY 20250815 40.0 CALL\">$CHWY 20250815 40.0 CALL$</a> will try &amp; play this call again 😉","text":"$CHWY 20250815 40.0 CALL$ will try & play this call again 😉","images":[{"img":"https://community-static.tradeup.com/news/83340010f66555d4c63802a28bdf40b7","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/459034328183416","isVote":1,"tweetType":1,"viewCount":813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":454100158079120,"gmtCreate":1751894503078,"gmtModify":1751894506810,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> topped up with a small parcel on the pre market pullback 🫣","listText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> topped up with a small parcel on the pre market pullback 🫣","text":"$INCANNEX HEALTHCARE LTD(IXHL)$ topped up with a small parcel on the pre market pullback 🫣","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/454100158079120","isVote":1,"tweetType":1,"viewCount":1077,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":410913346949264,"gmtCreate":1741353569192,"gmtModify":1741353572914,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"They need to make options tradable outside the standard hours as well","listText":"They need to make options tradable outside the standard hours as well","text":"They need to make options tradable outside the standard hours as well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/410913346949264","repostId":"1141380300","repostType":2,"isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":403152085623208,"gmtCreate":1739460092635,"gmtModify":1739460096178,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/LCID 20250221 3.0 CALL\">$LCID 20250221 3.0 CALL$</a> taking small profits&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/LCID 20250221 3.0 CALL\">$LCID 20250221 3.0 CALL$</a> taking small profits&nbsp;","text":"$LCID 20250221 3.0 CALL$ taking small profits","images":[{"img":"https://community-static.tradeup.com/news/302247fe720965919e5761f2867237e3","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/403152085623208","isVote":1,"tweetType":1,"viewCount":861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":402815150969080,"gmtCreate":1739371035378,"gmtModify":1739371038948,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NVDA 20250221 130.0 CALL\">$NVDA 20250221 130.0 CALL$</a> might do another quick flip today, maybe 🤔&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/NVDA 20250221 130.0 CALL\">$NVDA 20250221 130.0 CALL$</a> might do another quick flip today, maybe 🤔&nbsp;","text":"$NVDA 20250221 130.0 CALL$ might do another quick flip today, maybe 🤔","images":[{"img":"https://community-static.tradeup.com/news/f11ca0ff2ef160857067e0018af6a788","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/402815150969080","isVote":1,"tweetType":1,"viewCount":912,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":397536287330776,"gmtCreate":1738079692322,"gmtModify":1738079696176,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/U 20250221 22.0 CALL\">$U 20250221 22.0 CALL$</a> sold too early again, but other options plays are looking better setup. Maybe 🤦‍♂️🤔","listText":"<a href=\"https://ttm.financial/OPT/U 20250221 22.0 CALL\">$U 20250221 22.0 CALL$</a> sold too early again, but other options plays are looking better setup. Maybe 🤦‍♂️🤔","text":"$U 20250221 22.0 CALL$ sold too early again, but other options plays are looking better setup. Maybe 🤦‍♂️🤔","images":[{"img":"https://community-static.tradeup.com/news/83a655592c24e7bc7efae58ae95da7ad","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/397536287330776","isVote":1,"tweetType":1,"viewCount":844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":393724327330248,"gmtCreate":1737161355331,"gmtModify":1737161515175,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"$DXB USA & China licensing deals still to come","htmlText":"$DXB share price continues to hold up well since the Japan licensing deal annoucement. Company continues to lock in multi-country licensing deals prior to final Phase readout <a href=\"\">[财迷]&nbsp;&nbsp;</a>","listText":"$DXB share price continues to hold up well since the Japan licensing deal annoucement. Company continues to lock in multi-country licensing deals prior to final Phase readout <a href=\"\">[财迷]&nbsp;&nbsp;</a>","text":"$DXB share price continues to hold up well since the Japan licensing deal annoucement. Company continues to lock in multi-country licensing deals prior to final Phase readout [财迷]","images":[{"img":"https://community-static.tradeup.com/news/ba1361c7cd60d456b7a98f4962b3a6e5","width":"200","height":"200"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/393724327330248","isVote":1,"tweetType":1,"viewCount":625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":393658569507272,"gmtCreate":1737145301175,"gmtModify":1737145305109,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NVDA 20250117 137.0 CALL\">$NVDA 20250117 137.0 CALL$</a> Should've been over 100% profit but stuffed up my trade. Need to be more disciplined&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/NVDA 20250117 137.0 CALL\">$NVDA 20250117 137.0 CALL$</a> Should've been over 100% profit but stuffed up my trade. Need to be more disciplined&nbsp;","text":"$NVDA 20250117 137.0 CALL$ Should've been over 100% profit but stuffed up my trade. Need to be more disciplined","images":[{"img":"https://community-static.tradeup.com/news/d6ebf52c481c002582d5044c7d89acf1","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/393658569507272","isVote":1,"tweetType":1,"viewCount":940,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":390375406182768,"gmtCreate":1736351465705,"gmtModify":1736351469649,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/HAL 20250117 27.0 CALL\">$HAL 20250117 27.0 CALL$</a> profit should've been a lot higher but I got too greedy 😞","listText":"<a href=\"https://ttm.financial/OPT/HAL 20250117 27.0 CALL\">$HAL 20250117 27.0 CALL$</a> profit should've been a lot higher but I got too greedy 😞","text":"$HAL 20250117 27.0 CALL$ profit should've been a lot higher but I got too greedy 😞","images":[{"img":"https://community-static.tradeup.com/news/29a1ebe8d9cf24ea19e5c536ca40c7fb","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/390375406182768","isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":389810040521024,"gmtCreate":1736212291166,"gmtModify":1736216367489,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/XTIA\">$XTI Aerospace, Inc.(XTIA)$</a> Sold too early but a small win to kick off 2025 🤔","listText":"<a href=\"https://ttm.financial/S/XTIA\">$XTI Aerospace, Inc.(XTIA)$</a> Sold too early but a small win to kick off 2025 🤔","text":"$XTI Aerospace, Inc.(XTIA)$ Sold too early but a small win to kick off 2025 🤔","images":[{"img":"https://community-static.tradeup.com/news/1682ed2b2fe22abc71bf852df48e0d80","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":70,"commentSize":2,"repostSize":52,"link":"https://ttm.financial/post/389810040521024","isVote":1,"tweetType":1,"viewCount":3054,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000639","authorId":"9000000000000639","name":"tiger_cc","avatar":"https://community-static.tradeup.com/news/d6358062550fc5d8be9f8c6ad5aac6d3","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000639","authorIdStr":"9000000000000639"},"content":"Congratulations! As long as there's a profit, it's all good!","text":"Congratulations! As long as there's a profit, it's all good!","html":"Congratulations! As long as there's a profit, it's all good!"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":388098032652512,"gmtCreate":1735791999809,"gmtModify":1735792004041,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"USD 5 stock voucher. Good start to the year 💪","listText":"USD 5 stock voucher. Good start to the year 💪","text":"USD 5 stock voucher. Good start to the year 💪","images":[{"img":"https://community-static.tradeup.com/news/5a9e33bf6330767d516e3aae3572bff6"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/388098032652512","isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":373270496129520,"gmtCreate":1732176303256,"gmtModify":1732176307363,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OXY\">$Occidental(OXY)$&nbsp;</a><v-v data-views=\"1\"></v-v> Warren Buffet bought shares in the $60s, yet I'm waiting for it to break above $52 &amp; stay there 🥴&nbsp; Also, better-than-expected third-quarter earnings 🤷‍♂️","listText":"<a href=\"https://ttm.financial/S/OXY\">$Occidental(OXY)$&nbsp;</a><v-v data-views=\"1\"></v-v> Warren Buffet bought shares in the $60s, yet I'm waiting for it to break above $52 &amp; stay there 🥴&nbsp; Also, better-than-expected third-quarter earnings 🤷‍♂️","text":"$Occidental(OXY)$ Warren Buffet bought shares in the $60s, yet I'm waiting for it to break above $52 & stay there 🥴 Also, better-than-expected third-quarter earnings 🤷‍♂️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/373270496129520","isVote":1,"tweetType":1,"viewCount":2049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":372852641763432,"gmtCreate":1732038430842,"gmtModify":1732038434855,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a> Breaks 15c &amp; it'll be on 😉","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a> Breaks 15c &amp; it'll be on 😉","text":"$Tonix Pharmaceuticals(TNXP)$ Breaks 15c & it'll be on 😉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/372852641763432","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365342929940664,"gmtCreate":1730205385468,"gmtModify":1730205390028,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CETX\">$Cemtrex(CETX)$</a> Someone wants in 🤑","listText":"<a href=\"https://ttm.financial/S/CETX\">$Cemtrex(CETX)$</a> Someone wants in 🤑","text":"$Cemtrex(CETX)$ Someone wants in 🤑","images":[{"img":"https://community-static.tradeup.com/news/e9f339143abde6f2a2b727e4b76796ef","width":"1242","height":"915"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365342929940664","isVote":1,"tweetType":1,"viewCount":737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":363422867960040,"gmtCreate":1729752842913,"gmtModify":1729769992545,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CETX\">$Cemtrex(CETX)$</a> Support&nbsp;30c range, RSI oversold. Looking for a pop as it wants to move 💪 Gap $3.49-$5.23 🤤🤔","listText":"<a href=\"https://ttm.financial/S/CETX\">$Cemtrex(CETX)$</a> Support&nbsp;30c range, RSI oversold. Looking for a pop as it wants to move 💪 Gap $3.49-$5.23 🤤🤔","text":"$Cemtrex(CETX)$ Support 30c range, RSI oversold. Looking for a pop as it wants to move 💪 Gap $3.49-$5.23 🤤🤔","images":[{"img":"https://community-static.tradeup.com/news/e17e9fa1fc8cd4549e9d049f0d30d9cb","width":"1242","height":"2214"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363422867960040","isVote":1,"tweetType":1,"viewCount":1173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":329598541168816,"gmtCreate":1721474048481,"gmtModify":1721484032623,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> Does this company have a CEO? Doesn't seemed too concerned about the current state of affairs. MC is a joke","listText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> Does this company have a CEO? Doesn't seemed too concerned about the current state of affairs. MC is a joke","text":"$INCANNEX HEALTHCARE LTD(IXHL)$ Does this company have a CEO? Doesn't seemed too concerned about the current state of affairs. MC is a joke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":17,"repostSize":2,"link":"https://ttm.financial/post/329598541168816","isVote":1,"tweetType":1,"viewCount":1822,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4155205799870102","authorId":"4155205799870102","name":"Green Hornet","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"idStr":"4155205799870102","authorIdStr":"4155205799870102"},"content":"well I know I will be voting against everything that this corrupted leadership chucks up at the age. overpaid snakes comes to mind. geedy blood sucking vermin. free shares for themselves and no longer reply to concerns from actual paying shareholders. pitiful","text":"well I know I will be voting against everything that this corrupted leadership chucks up at the age. overpaid snakes comes to mind. geedy blood sucking vermin. free shares for themselves and no longer reply to concerns from actual paying shareholders. pitiful","html":"well I know I will be voting against everything that this corrupted leadership chucks up at the age. overpaid snakes comes to mind. geedy blood sucking vermin. free shares for themselves and no longer reply to concerns from actual paying shareholders. pitiful"},{"author":{"id":"4157599338499212","authorId":"4157599338499212","name":"Rusty02","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"idStr":"4157599338499212","authorIdStr":"4157599338499212"},"content":"problem with Incannex is greedy directors and now in a position after this Redomicile for even less reporting. Yes MC a joke but so are 2 directors in particular.","text":"problem with Incannex is greedy directors and now in a position after this Redomicile for even less reporting. Yes MC a joke but so are 2 directors in particular.","html":"problem with Incannex is greedy directors and now in a position after this Redomicile for even less reporting. Yes MC a joke but so are 2 directors in particular."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389810040521024,"gmtCreate":1736212291166,"gmtModify":1736216367489,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/XTIA\">$XTI Aerospace, Inc.(XTIA)$</a> Sold too early but a small win to kick off 2025 🤔","listText":"<a href=\"https://ttm.financial/S/XTIA\">$XTI Aerospace, Inc.(XTIA)$</a> Sold too early but a small win to kick off 2025 🤔","text":"$XTI Aerospace, Inc.(XTIA)$ Sold too early but a small win to kick off 2025 🤔","images":[{"img":"https://community-static.tradeup.com/news/1682ed2b2fe22abc71bf852df48e0d80","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":70,"commentSize":2,"repostSize":52,"link":"https://ttm.financial/post/389810040521024","isVote":1,"tweetType":1,"viewCount":3054,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000639","authorId":"9000000000000639","name":"tiger_cc","avatar":"https://community-static.tradeup.com/news/d6358062550fc5d8be9f8c6ad5aac6d3","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000639","authorIdStr":"9000000000000639"},"content":"Congratulations! As long as there's a profit, it's all good!","text":"Congratulations! As long as there's a profit, it's all good!","html":"Congratulations! As long as there's a profit, it's all good!"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":359953588351088,"gmtCreate":1728907270720,"gmtModify":1729154349063,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SGQ.AU\">$ST GEORGE MINING LTD(SGQ.AU)$</a> Niobium-REE acquisition approved by shareholders Reasons to like SGQ’s acquisition: 1. Niobium is a critical mineral. Governments want it, SGQ has it. 80% of the global niobium supply is controlled by one company CBMM. Niobium sits as the second highest risk metal on the critical materials list for both the EU and the US for supply concentration. 2. SGQ is capped at $55M post acquisition, much smaller than listed peers. Post acquisition SGQ will be capped at A$55M (at 2.5c/share). Peers that have made niobium discoveries include WA1 Resources ($842M) and Encounter Resources ($249M). SGQ can also be compared to peers that have defined Rare Earth Element projects including Brazilian Rare Earths ($550M) and Meteoric R","listText":"<a href=\"https://ttm.financial/S/SGQ.AU\">$ST GEORGE MINING LTD(SGQ.AU)$</a> Niobium-REE acquisition approved by shareholders Reasons to like SGQ’s acquisition: 1. Niobium is a critical mineral. Governments want it, SGQ has it. 80% of the global niobium supply is controlled by one company CBMM. Niobium sits as the second highest risk metal on the critical materials list for both the EU and the US for supply concentration. 2. SGQ is capped at $55M post acquisition, much smaller than listed peers. Post acquisition SGQ will be capped at A$55M (at 2.5c/share). Peers that have made niobium discoveries include WA1 Resources ($842M) and Encounter Resources ($249M). SGQ can also be compared to peers that have defined Rare Earth Element projects including Brazilian Rare Earths ($550M) and Meteoric R","text":"$ST GEORGE MINING LTD(SGQ.AU)$ Niobium-REE acquisition approved by shareholders Reasons to like SGQ’s acquisition: 1. Niobium is a critical mineral. Governments want it, SGQ has it. 80% of the global niobium supply is controlled by one company CBMM. Niobium sits as the second highest risk metal on the critical materials list for both the EU and the US for supply concentration. 2. SGQ is capped at $55M post acquisition, much smaller than listed peers. Post acquisition SGQ will be capped at A$55M (at 2.5c/share). Peers that have made niobium discoveries include WA1 Resources ($842M) and Encounter Resources ($249M). SGQ can also be compared to peers that have defined Rare Earth Element projects including Brazilian Rare Earths ($550M) and Meteoric R","images":[],"top":1,"highlighted":1,"essential":2,"paper":1,"likeSize":122,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/359953588351088","isVote":1,"tweetType":1,"viewCount":2260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355775096516864,"gmtCreate":1727868629171,"gmtModify":1727871427139,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> Annual report just released and still tumbleweeds from the CEO [Helpless]&nbsp; He needs to address shareholders concerns and the poor company performance. That's what CEOs do, he is well compensated [Serious]&nbsp;&nbsp;","listText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> Annual report just released and still tumbleweeds from the CEO [Helpless]&nbsp; He needs to address shareholders concerns and the poor company performance. That's what CEOs do, he is well compensated [Serious]&nbsp;&nbsp;","text":"$INCANNEX HEALTHCARE LTD(IXHL)$ Annual report just released and still tumbleweeds from the CEO [Helpless] He needs to address shareholders concerns and the poor company performance. That's what CEOs do, he is well compensated [Serious]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/355775096516864","repostId":"329598541168816","repostType":1,"repost":{"id":329598541168816,"gmtCreate":1721474048481,"gmtModify":1721484032623,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> Does this company have a CEO? Doesn't seemed too concerned about the current state of affairs. MC is a joke","listText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> Does this company have a CEO? Doesn't seemed too concerned about the current state of affairs. MC is a joke","text":"$INCANNEX HEALTHCARE LTD(IXHL)$ Does this company have a CEO? Doesn't seemed too concerned about the current state of affairs. MC is a joke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329598541168816","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":974,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4155205799870102","authorId":"4155205799870102","name":"Green Hornet","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"idStr":"4155205799870102","authorIdStr":"4155205799870102"},"content":"CEO and others now missing in action and no longer talking to those that email questions. They certainly did until they moved to the NASDAQ and we certainly have seen a big change. Seems they just like issuing free shares to themselves which is a total disgrace when they ignore the very same people that have got them there","text":"CEO and others now missing in action and no longer talking to those that email questions. They certainly did until they moved to the NASDAQ and we certainly have seen a big change. Seems they just like issuing free shares to themselves which is a total disgrace when they ignore the very same people that have got them there","html":"CEO and others now missing in action and no longer talking to those that email questions. They certainly did until they moved to the NASDAQ and we certainly have seen a big change. Seems they just like issuing free shares to themselves which is a total disgrace when they ignore the very same people that have got them there"},{"author":{"id":"4167173826336802","authorId":"4167173826336802","name":"Shakenbake","avatar":"https://community-static.tradeup.com/news/81dd3b5e2d5cad05f4ca17da2d28146e","crmLevel":11,"crmLevelSwitch":0,"idStr":"4167173826336802","authorIdStr":"4167173826336802"},"content":"Hopefully now trump is in we will see an upswing in the phyodelec sector. A bit of positive news flow would go along way though. BOD really do need to address shareholders a lot more I must admit","text":"Hopefully now trump is in we will see an upswing in the phyodelec sector. A bit of positive news flow would go along way though. BOD really do need to address shareholders a lot more I must admit","html":"Hopefully now trump is in we will see an upswing in the phyodelec sector. A bit of positive news flow would go along way though. BOD really do need to address shareholders a lot more I must admit"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373270496129520,"gmtCreate":1732176303256,"gmtModify":1732176307363,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OXY\">$Occidental(OXY)$&nbsp;</a><v-v data-views=\"1\"></v-v> Warren Buffet bought shares in the $60s, yet I'm waiting for it to break above $52 &amp; stay there 🥴&nbsp; Also, better-than-expected third-quarter earnings 🤷‍♂️","listText":"<a href=\"https://ttm.financial/S/OXY\">$Occidental(OXY)$&nbsp;</a><v-v data-views=\"1\"></v-v> Warren Buffet bought shares in the $60s, yet I'm waiting for it to break above $52 &amp; stay there 🥴&nbsp; Also, better-than-expected third-quarter earnings 🤷‍♂️","text":"$Occidental(OXY)$ Warren Buffet bought shares in the $60s, yet I'm waiting for it to break above $52 & stay there 🥴 Also, better-than-expected third-quarter earnings 🤷‍♂️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/373270496129520","isVote":1,"tweetType":1,"viewCount":2049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":363422867960040,"gmtCreate":1729752842913,"gmtModify":1729769992545,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CETX\">$Cemtrex(CETX)$</a> Support&nbsp;30c range, RSI oversold. Looking for a pop as it wants to move 💪 Gap $3.49-$5.23 🤤🤔","listText":"<a href=\"https://ttm.financial/S/CETX\">$Cemtrex(CETX)$</a> Support&nbsp;30c range, RSI oversold. Looking for a pop as it wants to move 💪 Gap $3.49-$5.23 🤤🤔","text":"$Cemtrex(CETX)$ Support 30c range, RSI oversold. Looking for a pop as it wants to move 💪 Gap $3.49-$5.23 🤤🤔","images":[{"img":"https://community-static.tradeup.com/news/e17e9fa1fc8cd4549e9d049f0d30d9cb","width":"1242","height":"2214"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/363422867960040","isVote":1,"tweetType":1,"viewCount":1173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":454100158079120,"gmtCreate":1751894503078,"gmtModify":1751894506810,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> topped up with a small parcel on the pre market pullback 🫣","listText":"<a href=\"https://ttm.financial/S/IXHL\">$INCANNEX HEALTHCARE LTD(IXHL)$</a> topped up with a small parcel on the pre market pullback 🫣","text":"$INCANNEX HEALTHCARE LTD(IXHL)$ topped up with a small parcel on the pre market pullback 🫣","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/454100158079120","isVote":1,"tweetType":1,"viewCount":1077,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":507169696534648,"gmtCreate":1764842415202,"gmtModify":1764842418993,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"Looking good&nbsp;","listText":"Looking good&nbsp;","text":"Looking good","images":[{"img":"https://community-static.tradeup.com/news/1001e39388f21422f90a3d23b2496753","width":"1242","height":"1879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/507169696534648","isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":507169331593976,"gmtCreate":1764842348449,"gmtModify":1764842352467,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"Major regulatory validation; merger and acquisitions appeal; supports global regulatory strategy; top tier milestone 💪","listText":"Major regulatory validation; merger and acquisitions appeal; supports global regulatory strategy; top tier milestone 💪","text":"Major regulatory validation; merger and acquisitions appeal; supports global regulatory strategy; top tier milestone 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/507169331593976","repostId":"2588049886","repostType":2,"repost":{"id":"2588049886","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1764766906,"share":"https://ttm.financial/m/news/2588049886?lang=&edition=fundamental","pubTime":"2025-12-03 21:01","market":"us","language":"en","title":"FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049886","media":"Reuters","summary":"Incannex Healthcare Inc. announced that the U.S. Food and Drug Administration  has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea . The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Grants <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation to <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> for IHL-42X in Obstructive Sleep Apnea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea (OSA). The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-117571), on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Grants <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation to <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> for IHL-42X in Obstructive Sleep Apnea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea (OSA). The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-117571), on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2JMx64:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2588049886","content_text":"FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea\n    \n\nIncannex Healthcare Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea (OSA). The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-117571), on December 03, 2025, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"IXHL":0.9}},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":410913346949264,"gmtCreate":1741353569192,"gmtModify":1741353572914,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"They need to make options tradable outside the standard hours as well","listText":"They need to make options tradable outside the standard hours as well","text":"They need to make options tradable outside the standard hours as well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/410913346949264","repostId":"1141380300","repostType":2,"repost":{"id":"1141380300","kind":"news","pubTimestamp":1741353000,"share":"https://ttm.financial/m/news/1141380300?lang=&edition=fundamental","pubTime":"2025-03-07 21:10","market":"us","language":"en","title":"Nasdaq Joins Exchanges Seeking to Offer Round-the-Clock Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141380300","media":"Bloomberg","summary":"Nasdaq Inc. plans to offer 24-hour trading on its equities exchange, the latest venue seeking to capitalize on growing global demand for US stocks.The second-largest US exchange operator plans to enab","content":"<div>\n<p>Nasdaq Inc. plans to offer 24-hour trading on its equities exchange, the latest venue seeking to capitalize on growing global demand for US stocks.The second-largest US exchange operator plans to ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2025-03-07/nasdaq-joins-exchanges-seeking-to-offer-round-the-clock-trading?srnd=homepage-americas\">Web Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Joins Exchanges Seeking to Offer Round-the-Clock Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Joins Exchanges Seeking to Offer Round-the-Clock Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-07 21:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2025-03-07/nasdaq-joins-exchanges-seeking-to-offer-round-the-clock-trading?srnd=homepage-americas><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nasdaq Inc. plans to offer 24-hour trading on its equities exchange, the latest venue seeking to capitalize on growing global demand for US stocks.The second-largest US exchange operator plans to ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2025-03-07/nasdaq-joins-exchanges-seeking-to-offer-round-the-clock-trading?srnd=homepage-americas\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","NDAQ":"纳斯达克OMX交易所"},"source_url":"https://www.bloomberg.com/news/articles/2025-03-07/nasdaq-joins-exchanges-seeking-to-offer-round-the-clock-trading?srnd=homepage-americas","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141380300","content_text":"Nasdaq Inc. plans to offer 24-hour trading on its equities exchange, the latest venue seeking to capitalize on growing global demand for US stocks.The second-largest US exchange operator plans to enable the extended trading five days a week, according to Nasdaq President Tal Cohen. It expects to start round-the-clock trading in the second half of 2026, pending regulatory approval and alignment with the rest of the industry, Cohen said in a post on LinkedIn.The move follows plans by other exchanges: Cboe Global Markets Inc. said last month it would extend trading on its equities exchange to 24 hours, five days a week, pending regulatory approval. The New York Stock Exchange filed its own application in October with plans to offer trading 22 hours on weekdays.Nasdaq’s Cohen pointed to heightened interest in US markets from retail investors in different time zones. Still, he said markets and investors need to consider the risks associated with increased volatility and higher transaction costs that can come as a result of the expanded trading hours. Despite the increase in overnight trading, liquidity is still “significantly lower” during those hours, according to Cohen.The plans also hinge on an update to the securities information processor, also known as the SIP, which displays the best bid and offer price of a stock on an exchange at the time of transaction. For overnight trading to take effect on public stock venues, this data needs to be updated to accommodate the extra hours.Nasdaq will work with other industry participants to mitigate these concerns and risks, Cohen said. It’s forming a group to do so, according to a spokesperson.“The question is not whether we can build a market that operates 24/5, but how we do so in a way that strengthens investor confidence in US capital markets today,” said Cohen.Extended trading hours became more common during the pandemic, allowing investors to react to market-moving events immediately. Firms such as Robinhood Markets Inc. and Interactive Brokers Group Inc. started enabling customers to buy and sell US stocks 24 hours a day, five days a week on off-exchange venues like Blue Ocean’s alternative-trading system.Venues that allow nonstop stock trading have split Wall Street. Proponents say investors both in the US and overseas want the ability to react and access stocks outside of US market hours. Opponents have warned that the quality of trading may suffer from lower volume, which can make pricing less precise.The majority of trading activity still occurs around the infamous opening and closing bell across the largest stock exchanges in US markets. With the additional hours, a lingering question becomes whether institutional traders will start to trade outside of those moments when volumes are higher.","news_type":1,"symbols_score_info":{".DJI":1.1,".IXIC":1.1,"NDAQ":1.1,".SPX":1.1}},"isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":496375082554232,"gmtCreate":1762207751356,"gmtModify":1762219474894,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/OPT/GRAB 20251121 7.0 CALL\">$GRAB 20251121 7.0 CALL$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/GRAB 20251121 7.0 CALL\">$GRAB 20251121 7.0 CALL$</a>&nbsp;","text":"$GRAB 20251121 7.0 CALL$","images":[{"img":"https://community-static.tradeup.com/news/297d25fb60c788743a79c8c59aafc8f1","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/496375082554232","isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":495445381021760,"gmtCreate":1761988929153,"gmtModify":1761988932855,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"","htmlText":"Bullish on earnings. 21 Nov $7 call options 🤔","listText":"Bullish on earnings. 21 Nov $7 call options 🤔","text":"Bullish on earnings. 21 Nov $7 call options 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/495445381021760","repostId":"1160098839","repostType":2,"repost":{"id":"1160098839","kind":"news","weMediaInfo":{"introduction":"Focus on earnings forecast and in-depth analysis","home_visible":1,"media_name":"Earnings Agent","id":"1025659746","head_image":"https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f"},"pubTimestamp":1761737569,"share":"https://ttm.financial/m/news/1160098839?lang=&edition=fundamental","pubTime":"2025-10-29 19:32","market":"us","language":"zh","title":"Earnings Preview | Grab's Q3 EPS Has Room for Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=1160098839","media":"Earnings Agent","summary":"Summary: Southeast Asian ride-hailing and food delivery giant  $Grab Holdings(GRAB)$  will release its third-quarter earnings after the U.S. market closes on November 3.Q2 ReviewIn Q2 2025, Grab's mon","content":"<p><strong><em>Summary:</em></strong><em> Southeast Asian ride-hailing and food delivery giant </em><a href=\"https://laohu8.com/S/GRAB\">Grab Holdings</a> <em>will release its third-quarter earnings after the U.S. market closes on November 3.</em></p><h3 id=\"id_771382504\">Q2 Review</h3><p>In Q2 2025, Grab's monthly transacting users (MTUs) reached 46.2 million, with revenue growing 23% year-over-year to $819 million. Gross Merchandise Value (GMV) for on-demand services (mobility and deliveries) increased 21% year-over-year to $5.35 billion. Adjusted EBITDA grew for the 14th consecutive quarter, reaching $109 million. The company also achieved a net profit of $20 million, doubling from the previous quarter.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a724fb9ff1ea35d3a85bb1c89cb9a72\" title=\"\" tg-width=\"1080\" tg-height=\"581\"></p><h3 id=\"id_1053722042\">Q3 Expectations</h3><p>Management guidance for Q3 includes year-over-year revenue growth, stable gross margin range, quarter-over-quarter improvement in adjusted EPS, and continued improvement in net profit supported by operational efficiency optimization. </p><p>According to Tiger Trade data, Grab expects total revenue of $872 million, earnings per share of $0.014, and EBIT of $4 million in the third quarter.</p><h3 id=\"id_4188979156\">Outlook for This Quarter</h3><p><strong>Resilience in Mobility Demand and Fine-tuning of Supply Management</strong></p><p>Q3 saw continued recovery in travel and commuting demand. Institutional previews generally point out that Mobility order volume and pricing resilience are driving revenue. In the Q2 earnings call, management emphasized dynamic balancing between user experience and driver supply, which will continue to be implemented in Q3. This helps reduce waiting times and cancellation rates during peak hours, improving order completion rates, thus positively impacting revenue and gross margin. Combined with preview and research report assumptions, under the seasonal peak, the Mobility segment's GMV and take rate remain stable. Along with subsidy optimization, the profit contribution per order increases, supporting adjusted EPS. If cross-border travel remains stable, this segment's marginal contribution to group revenue is expected to strengthen, increasing market focus on Q3 profit realization, especially on the stability of unit economics during the peak season.</p><p><strong>Delivery Efficiency Upgrade and Synergy with Advertising Placement</strong></p><p>Deliveries showed a profit margin recovery trajectory in Q2, with multiple performance interpretations emphasizing the platform's structural optimization between dispatch algorithms, merchant subsidies, and user-side delivery fees. Entering Q3, institutional outlooks point to advertising as an important incremental factor: in merchant placement and category operations, the order conversion-based billing model increases the certainty of advertising revenue while reducing reliance on high subsidies. Improved fulfillment efficiency not only brings direct cost reduction but also enhances merchant ROI through more precise traffic distribution, resulting in both revenue and profit margin improvements. Research views generally believe that the Deliveries gross margin maintains an improvement range, coupled with improved advertising conversion rates, providing room for improvement in Q3 adjusted EBITDA and EPS. The core of this path lies in the steady improvement of unit economics, presenting parallel characteristics of revenue growth and profit margin recovery on the financial side, with stronger ability to hedge demand fluctuations.</p><p><strong>Stable Operation of Financial Services and Boundary Control of Risk Costs</strong></p><p>The Q2 earnings call mentioned that risk costs for financial services were under control, providing a more stable profit base for Q3. Institutional views suggest that the payment closed-loop and risk control model optimization reduce delinquency and loss rates, releasing more capital space available for growth. Combined with the relatively stable macroeconomic environment in Q3, this business forms a mild increase in net profit and adjusted EPS. Management emphasizes the pace of prioritizing profit quality, making Q3 performance more focused on balancing risk and return, and increasing user stickiness and cross-business synergy through penetration with mobility and delivery. If risk control indicators continue to improve as in Q2, market confidence in Q3 net profit margin recovery will strengthen, while laying the foundation for steady growth in subsequent quarters.</p><p><strong>Efficiency-Driven Cost Structure Optimization and Improved Profitability Certainty</strong></p><p>Multiple institutions emphasize continued operational efficiency optimization in their Q3 outlooks, including vehicle and rider supply-demand matching, shortened fulfillment paths, and automation of customer service and risk control. Q2 results have already reflected positive changes in unit economics, and entering Q3, these improvements will further act on gross margin and net profit. Market views indicate that management's balancing strategy between subsidies and commissions continues, reducing inefficient subsidies, increasing high-quality order flow, and improving the stability of advertising and merchant service revenue. This strategy not only enhances the profit recognition for this quarter but also reduces performance volatility, providing structural support for adjusted EPS. If the optimization path remains consistent, the market will have higher confidence in Q3 performance delivery and full-year guidance credibility, with valuation responding more elastically to profit quality improvements.</p><p><strong>Synergistic Impact of Regional Dynamics and Seasonal Factors</strong></p><p>Previews and research reports mention that under the recovery environment of major cities and cross-border tourism lines in Q3, regional dynamics may show divergence but remain positive overall. High-frequency orders in core cities are more resilient during peak seasons, with the platform using differentiated rates and supply strategies to shorten waiting times and improve peak-time fulfillment capabilities, thus maintaining stable take rates and gross margins. The positive effects of seasonal factors match advertising placement rhythms, helping to improve merchant exposure and conversion, thereby promoting order density in food and goods delivery. If demand declines in some regions, the platform uses optimized scheduling and subsidy structures as buffers to mitigate the impact on profit margins, demonstrating flexibility in allocation and risk hedging capabilities across different regions.</p><p><strong>Cross-Penetration and Enhancement of User Lifetime Value</strong></p><p>Institutions consistently emphasize the enhancement of user lifetime value through cross-penetration between mobility, delivery, and financial services. In Q3, under the combination of membership benefits, targeted subsidies, and payment discounts, active user rates and repurchase frequency increase, supporting order density and advertising placement effectiveness. Conversion-based advertising billing improves merchant ROI, encouraging more merchants to participate in platform promotions and recommended position optimization, forming a stable revenue increment. Improved user retention across multiple business scenarios allows the platform to reduce customer acquisition costs and improve overall unit economics, ultimately reflected in continuous recovery of gross margin and adjusted EPS.</p><h3 id=\"id_1378994986\">Conclusion</h3><p>The core focus for Q3 is on continued optimization of unit economics and improvement in profit quality. The Mobility segment, with peak season and supply fine-tuning, sees order completion rates and pricing resilience supporting revenue and gross margins. The Delivery segment achieves dual improvement in cost structure and revenue quality through fulfillment efficiency upgrades and conversion-based advertising synergy. Financial services continue to control risk costs, providing a solid profit base for overall performance.</p><p>Institutional views generally believe there is room for improvement in adjusted EPS, with management having more confidence in the continuity of gross margin and profit recovery. From Q2 performance and Q3 outlook, Grab's growth path emphasizes both efficiency and quality. If this direction is validated, it will be conducive to enhancing market trust in full-year guidance and expectations for subsequent operational performance.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earnings Preview | Grab's Q3 EPS Has Room for Improvement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarnings Preview | Grab's Q3 EPS Has Room for Improvement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1025659746\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/decf3d8a922fc5c1c1d787bf8b36173f);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Earnings Agent </p>\n<p class=\"h-time\">2025-10-29 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><strong><em>Summary:</em></strong><em> Southeast Asian ride-hailing and food delivery giant </em><a href=\"https://laohu8.com/S/GRAB\">Grab Holdings</a> <em>will release its third-quarter earnings after the U.S. market closes on November 3.</em></p><h3 id=\"id_771382504\">Q2 Review</h3><p>In Q2 2025, Grab's monthly transacting users (MTUs) reached 46.2 million, with revenue growing 23% year-over-year to $819 million. Gross Merchandise Value (GMV) for on-demand services (mobility and deliveries) increased 21% year-over-year to $5.35 billion. Adjusted EBITDA grew for the 14th consecutive quarter, reaching $109 million. The company also achieved a net profit of $20 million, doubling from the previous quarter.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a724fb9ff1ea35d3a85bb1c89cb9a72\" title=\"\" tg-width=\"1080\" tg-height=\"581\"></p><h3 id=\"id_1053722042\">Q3 Expectations</h3><p>Management guidance for Q3 includes year-over-year revenue growth, stable gross margin range, quarter-over-quarter improvement in adjusted EPS, and continued improvement in net profit supported by operational efficiency optimization. </p><p>According to Tiger Trade data, Grab expects total revenue of $872 million, earnings per share of $0.014, and EBIT of $4 million in the third quarter.</p><h3 id=\"id_4188979156\">Outlook for This Quarter</h3><p><strong>Resilience in Mobility Demand and Fine-tuning of Supply Management</strong></p><p>Q3 saw continued recovery in travel and commuting demand. Institutional previews generally point out that Mobility order volume and pricing resilience are driving revenue. In the Q2 earnings call, management emphasized dynamic balancing between user experience and driver supply, which will continue to be implemented in Q3. This helps reduce waiting times and cancellation rates during peak hours, improving order completion rates, thus positively impacting revenue and gross margin. Combined with preview and research report assumptions, under the seasonal peak, the Mobility segment's GMV and take rate remain stable. Along with subsidy optimization, the profit contribution per order increases, supporting adjusted EPS. If cross-border travel remains stable, this segment's marginal contribution to group revenue is expected to strengthen, increasing market focus on Q3 profit realization, especially on the stability of unit economics during the peak season.</p><p><strong>Delivery Efficiency Upgrade and Synergy with Advertising Placement</strong></p><p>Deliveries showed a profit margin recovery trajectory in Q2, with multiple performance interpretations emphasizing the platform's structural optimization between dispatch algorithms, merchant subsidies, and user-side delivery fees. Entering Q3, institutional outlooks point to advertising as an important incremental factor: in merchant placement and category operations, the order conversion-based billing model increases the certainty of advertising revenue while reducing reliance on high subsidies. Improved fulfillment efficiency not only brings direct cost reduction but also enhances merchant ROI through more precise traffic distribution, resulting in both revenue and profit margin improvements. Research views generally believe that the Deliveries gross margin maintains an improvement range, coupled with improved advertising conversion rates, providing room for improvement in Q3 adjusted EBITDA and EPS. The core of this path lies in the steady improvement of unit economics, presenting parallel characteristics of revenue growth and profit margin recovery on the financial side, with stronger ability to hedge demand fluctuations.</p><p><strong>Stable Operation of Financial Services and Boundary Control of Risk Costs</strong></p><p>The Q2 earnings call mentioned that risk costs for financial services were under control, providing a more stable profit base for Q3. Institutional views suggest that the payment closed-loop and risk control model optimization reduce delinquency and loss rates, releasing more capital space available for growth. Combined with the relatively stable macroeconomic environment in Q3, this business forms a mild increase in net profit and adjusted EPS. Management emphasizes the pace of prioritizing profit quality, making Q3 performance more focused on balancing risk and return, and increasing user stickiness and cross-business synergy through penetration with mobility and delivery. If risk control indicators continue to improve as in Q2, market confidence in Q3 net profit margin recovery will strengthen, while laying the foundation for steady growth in subsequent quarters.</p><p><strong>Efficiency-Driven Cost Structure Optimization and Improved Profitability Certainty</strong></p><p>Multiple institutions emphasize continued operational efficiency optimization in their Q3 outlooks, including vehicle and rider supply-demand matching, shortened fulfillment paths, and automation of customer service and risk control. Q2 results have already reflected positive changes in unit economics, and entering Q3, these improvements will further act on gross margin and net profit. Market views indicate that management's balancing strategy between subsidies and commissions continues, reducing inefficient subsidies, increasing high-quality order flow, and improving the stability of advertising and merchant service revenue. This strategy not only enhances the profit recognition for this quarter but also reduces performance volatility, providing structural support for adjusted EPS. If the optimization path remains consistent, the market will have higher confidence in Q3 performance delivery and full-year guidance credibility, with valuation responding more elastically to profit quality improvements.</p><p><strong>Synergistic Impact of Regional Dynamics and Seasonal Factors</strong></p><p>Previews and research reports mention that under the recovery environment of major cities and cross-border tourism lines in Q3, regional dynamics may show divergence but remain positive overall. High-frequency orders in core cities are more resilient during peak seasons, with the platform using differentiated rates and supply strategies to shorten waiting times and improve peak-time fulfillment capabilities, thus maintaining stable take rates and gross margins. The positive effects of seasonal factors match advertising placement rhythms, helping to improve merchant exposure and conversion, thereby promoting order density in food and goods delivery. If demand declines in some regions, the platform uses optimized scheduling and subsidy structures as buffers to mitigate the impact on profit margins, demonstrating flexibility in allocation and risk hedging capabilities across different regions.</p><p><strong>Cross-Penetration and Enhancement of User Lifetime Value</strong></p><p>Institutions consistently emphasize the enhancement of user lifetime value through cross-penetration between mobility, delivery, and financial services. In Q3, under the combination of membership benefits, targeted subsidies, and payment discounts, active user rates and repurchase frequency increase, supporting order density and advertising placement effectiveness. Conversion-based advertising billing improves merchant ROI, encouraging more merchants to participate in platform promotions and recommended position optimization, forming a stable revenue increment. Improved user retention across multiple business scenarios allows the platform to reduce customer acquisition costs and improve overall unit economics, ultimately reflected in continuous recovery of gross margin and adjusted EPS.</p><h3 id=\"id_1378994986\">Conclusion</h3><p>The core focus for Q3 is on continued optimization of unit economics and improvement in profit quality. The Mobility segment, with peak season and supply fine-tuning, sees order completion rates and pricing resilience supporting revenue and gross margins. The Delivery segment achieves dual improvement in cost structure and revenue quality through fulfillment efficiency upgrades and conversion-based advertising synergy. Financial services continue to control risk costs, providing a solid profit base for overall performance.</p><p>Institutional views generally believe there is room for improvement in adjusted EPS, with management having more confidence in the continuity of gross margin and profit recovery. From Q2 performance and Q3 outlook, Grab's growth path emphasizes both efficiency and quality. If this direction is validated, it will be conducive to enhancing market trust in full-year guidance and expectations for subsequent operational performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160098839","content_text":"Summary: Southeast Asian ride-hailing and food delivery giant Grab Holdings will release its third-quarter earnings after the U.S. market closes on November 3.Q2 ReviewIn Q2 2025, Grab's monthly transacting users (MTUs) reached 46.2 million, with revenue growing 23% year-over-year to $819 million. Gross Merchandise Value (GMV) for on-demand services (mobility and deliveries) increased 21% year-over-year to $5.35 billion. Adjusted EBITDA grew for the 14th consecutive quarter, reaching $109 million. The company also achieved a net profit of $20 million, doubling from the previous quarter.Q3 ExpectationsManagement guidance for Q3 includes year-over-year revenue growth, stable gross margin range, quarter-over-quarter improvement in adjusted EPS, and continued improvement in net profit supported by operational efficiency optimization. According to Tiger Trade data, Grab expects total revenue of $872 million, earnings per share of $0.014, and EBIT of $4 million in the third quarter.Outlook for This QuarterResilience in Mobility Demand and Fine-tuning of Supply ManagementQ3 saw continued recovery in travel and commuting demand. Institutional previews generally point out that Mobility order volume and pricing resilience are driving revenue. In the Q2 earnings call, management emphasized dynamic balancing between user experience and driver supply, which will continue to be implemented in Q3. This helps reduce waiting times and cancellation rates during peak hours, improving order completion rates, thus positively impacting revenue and gross margin. Combined with preview and research report assumptions, under the seasonal peak, the Mobility segment's GMV and take rate remain stable. Along with subsidy optimization, the profit contribution per order increases, supporting adjusted EPS. If cross-border travel remains stable, this segment's marginal contribution to group revenue is expected to strengthen, increasing market focus on Q3 profit realization, especially on the stability of unit economics during the peak season.Delivery Efficiency Upgrade and Synergy with Advertising PlacementDeliveries showed a profit margin recovery trajectory in Q2, with multiple performance interpretations emphasizing the platform's structural optimization between dispatch algorithms, merchant subsidies, and user-side delivery fees. Entering Q3, institutional outlooks point to advertising as an important incremental factor: in merchant placement and category operations, the order conversion-based billing model increases the certainty of advertising revenue while reducing reliance on high subsidies. Improved fulfillment efficiency not only brings direct cost reduction but also enhances merchant ROI through more precise traffic distribution, resulting in both revenue and profit margin improvements. Research views generally believe that the Deliveries gross margin maintains an improvement range, coupled with improved advertising conversion rates, providing room for improvement in Q3 adjusted EBITDA and EPS. The core of this path lies in the steady improvement of unit economics, presenting parallel characteristics of revenue growth and profit margin recovery on the financial side, with stronger ability to hedge demand fluctuations.Stable Operation of Financial Services and Boundary Control of Risk CostsThe Q2 earnings call mentioned that risk costs for financial services were under control, providing a more stable profit base for Q3. Institutional views suggest that the payment closed-loop and risk control model optimization reduce delinquency and loss rates, releasing more capital space available for growth. Combined with the relatively stable macroeconomic environment in Q3, this business forms a mild increase in net profit and adjusted EPS. Management emphasizes the pace of prioritizing profit quality, making Q3 performance more focused on balancing risk and return, and increasing user stickiness and cross-business synergy through penetration with mobility and delivery. If risk control indicators continue to improve as in Q2, market confidence in Q3 net profit margin recovery will strengthen, while laying the foundation for steady growth in subsequent quarters.Efficiency-Driven Cost Structure Optimization and Improved Profitability CertaintyMultiple institutions emphasize continued operational efficiency optimization in their Q3 outlooks, including vehicle and rider supply-demand matching, shortened fulfillment paths, and automation of customer service and risk control. Q2 results have already reflected positive changes in unit economics, and entering Q3, these improvements will further act on gross margin and net profit. Market views indicate that management's balancing strategy between subsidies and commissions continues, reducing inefficient subsidies, increasing high-quality order flow, and improving the stability of advertising and merchant service revenue. This strategy not only enhances the profit recognition for this quarter but also reduces performance volatility, providing structural support for adjusted EPS. If the optimization path remains consistent, the market will have higher confidence in Q3 performance delivery and full-year guidance credibility, with valuation responding more elastically to profit quality improvements.Synergistic Impact of Regional Dynamics and Seasonal FactorsPreviews and research reports mention that under the recovery environment of major cities and cross-border tourism lines in Q3, regional dynamics may show divergence but remain positive overall. High-frequency orders in core cities are more resilient during peak seasons, with the platform using differentiated rates and supply strategies to shorten waiting times and improve peak-time fulfillment capabilities, thus maintaining stable take rates and gross margins. The positive effects of seasonal factors match advertising placement rhythms, helping to improve merchant exposure and conversion, thereby promoting order density in food and goods delivery. If demand declines in some regions, the platform uses optimized scheduling and subsidy structures as buffers to mitigate the impact on profit margins, demonstrating flexibility in allocation and risk hedging capabilities across different regions.Cross-Penetration and Enhancement of User Lifetime ValueInstitutions consistently emphasize the enhancement of user lifetime value through cross-penetration between mobility, delivery, and financial services. In Q3, under the combination of membership benefits, targeted subsidies, and payment discounts, active user rates and repurchase frequency increase, supporting order density and advertising placement effectiveness. Conversion-based advertising billing improves merchant ROI, encouraging more merchants to participate in platform promotions and recommended position optimization, forming a stable revenue increment. Improved user retention across multiple business scenarios allows the platform to reduce customer acquisition costs and improve overall unit economics, ultimately reflected in continuous recovery of gross margin and adjusted EPS.ConclusionThe core focus for Q3 is on continued optimization of unit economics and improvement in profit quality. The Mobility segment, with peak season and supply fine-tuning, sees order completion rates and pricing resilience supporting revenue and gross margins. The Delivery segment achieves dual improvement in cost structure and revenue quality through fulfillment efficiency upgrades and conversion-based advertising synergy. Financial services continue to control risk costs, providing a solid profit base for overall performance.Institutional views generally believe there is room for improvement in adjusted EPS, with management having more confidence in the continuity of gross margin and profit recovery. From Q2 performance and Q3 outlook, Grab's growth path emphasizes both efficiency and quality. If this direction is validated, it will be conducive to enhancing market trust in full-year guidance and expectations for subsequent operational performance.","news_type":1,"symbols_score_info":{"GRAB":1.1}},"isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":462272078565528,"gmtCreate":1753877678434,"gmtModify":1753877682283,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"Excuse the language. But faaark that's fantastic 👏","listText":"Excuse the language. But faaark that's fantastic 👏","text":"Excuse the language. But faaark that's fantastic 👏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/462272078565528","repostId":"2555049322","repostType":2,"repost":{"id":"2555049322","kind":"live","pubTimestamp":1753876802,"share":"https://ttm.financial/m/news/2555049322?lang=&edition=fundamental","pubTime":"2025-07-30 20:00","market":"nz","language":"en","title":"Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X","url":"https://stock-news.laohu8.com/highlight/detail?id=2555049322","media":"THOMSON REUTERS","summary":"Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X","content":"<html><body><p>Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-30 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUA1YQT1J:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUA1YQT1J:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUA1YQT1J:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2555049322","content_text":"Incannex Reports Positive Topline Results From Reposa Phase 2 Trial of Ihl-42X","news_type":1,"symbols_score_info":{"IXHL":0.9}},"isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":459034328183416,"gmtCreate":1753105721800,"gmtModify":1753105725370,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/CHWY 20250815 40.0 CALL\">$CHWY 20250815 40.0 CALL$</a> will try &amp; play this call again 😉","listText":"<a href=\"https://ttm.financial/OPT/CHWY 20250815 40.0 CALL\">$CHWY 20250815 40.0 CALL$</a> will try &amp; play this call again 😉","text":"$CHWY 20250815 40.0 CALL$ will try & play this call again 😉","images":[{"img":"https://community-static.tradeup.com/news/83340010f66555d4c63802a28bdf40b7","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/459034328183416","isVote":1,"tweetType":1,"viewCount":813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":372852641763432,"gmtCreate":1732038430842,"gmtModify":1732038434855,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a> Breaks 15c &amp; it'll be on 😉","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a> Breaks 15c &amp; it'll be on 😉","text":"$Tonix Pharmaceuticals(TNXP)$ Breaks 15c & it'll be on 😉","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/372852641763432","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":343899897012448,"gmtCreate":1724989544561,"gmtModify":1724991972332,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DXB.AU\">$DIMERIX LTD(DXB.AU)$</a> +9.8% so far today. Hopefully US or China licensing deal is nearing completion 🤞","listText":"<a href=\"https://ttm.financial/S/DXB.AU\">$DIMERIX LTD(DXB.AU)$</a> +9.8% so far today. Hopefully US or China licensing deal is nearing completion 🤞","text":"$DIMERIX LTD(DXB.AU)$ +9.8% so far today. Hopefully US or China licensing deal is nearing completion 🤞","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/343899897012448","isVote":1,"tweetType":1,"viewCount":605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":403152085623208,"gmtCreate":1739460092635,"gmtModify":1739460096178,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/LCID 20250221 3.0 CALL\">$LCID 20250221 3.0 CALL$</a> taking small profits&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/LCID 20250221 3.0 CALL\">$LCID 20250221 3.0 CALL$</a> taking small profits&nbsp;","text":"$LCID 20250221 3.0 CALL$ taking small profits","images":[{"img":"https://community-static.tradeup.com/news/302247fe720965919e5761f2867237e3","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/403152085623208","isVote":1,"tweetType":1,"viewCount":861,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":402815150969080,"gmtCreate":1739371035378,"gmtModify":1739371038948,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NVDA 20250221 130.0 CALL\">$NVDA 20250221 130.0 CALL$</a> might do another quick flip today, maybe 🤔&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/NVDA 20250221 130.0 CALL\">$NVDA 20250221 130.0 CALL$</a> might do another quick flip today, maybe 🤔&nbsp;","text":"$NVDA 20250221 130.0 CALL$ might do another quick flip today, maybe 🤔","images":[{"img":"https://community-static.tradeup.com/news/f11ca0ff2ef160857067e0018af6a788","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/402815150969080","isVote":1,"tweetType":1,"viewCount":912,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":397536287330776,"gmtCreate":1738079692322,"gmtModify":1738079696176,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/U 20250221 22.0 CALL\">$U 20250221 22.0 CALL$</a> sold too early again, but other options plays are looking better setup. Maybe 🤦‍♂️🤔","listText":"<a href=\"https://ttm.financial/OPT/U 20250221 22.0 CALL\">$U 20250221 22.0 CALL$</a> sold too early again, but other options plays are looking better setup. Maybe 🤦‍♂️🤔","text":"$U 20250221 22.0 CALL$ sold too early again, but other options plays are looking better setup. Maybe 🤦‍♂️🤔","images":[{"img":"https://community-static.tradeup.com/news/83a655592c24e7bc7efae58ae95da7ad","width":"1044","height":"1683"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/397536287330776","isVote":1,"tweetType":1,"viewCount":844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":393724327330248,"gmtCreate":1737161355331,"gmtModify":1737161515175,"author":{"id":"4090118087808150","authorId":"4090118087808150","name":"Flanostu","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4090118087808150","authorIdStr":"4090118087808150"},"themes":[],"title":"$DXB USA & China licensing deals still to come","htmlText":"$DXB share price continues to hold up well since the Japan licensing deal annoucement. Company continues to lock in multi-country licensing deals prior to final Phase readout <a href=\"\">[财迷]&nbsp;&nbsp;</a>","listText":"$DXB share price continues to hold up well since the Japan licensing deal annoucement. Company continues to lock in multi-country licensing deals prior to final Phase readout <a href=\"\">[财迷]&nbsp;&nbsp;</a>","text":"$DXB share price continues to hold up well since the Japan licensing deal annoucement. Company continues to lock in multi-country licensing deals prior to final Phase readout [财迷]","images":[{"img":"https://community-static.tradeup.com/news/ba1361c7cd60d456b7a98f4962b3a6e5","width":"200","height":"200"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/393724327330248","isVote":1,"tweetType":1,"viewCount":625,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0}],"lives":[]}